Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...

For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted to the intensive care unit ...

GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.

Doctors are alerted by digital clubbing, a bulbous swelling of fingertips, a sign known since ancient times. This often ...

The 3TR project aims to transform the understanding and treatment of immune-mediated diseases, with its core principles in ...

Anti-IL5 therapy significantly reduces moderate and severe exacerbations in asthma and COPD, preventing major ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

GSK and Empirico ink license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases: London, UK Wednesday, October 29, 2025, 09:00 Hr ...

Shortness of breath when walking short distances can occur suddenly or be a chronic condition. It should be evaluated, as it ...

Air pollution in India is driving a surge in chronic illnesses and deaths, says the State of Global Air 2025 report, with the ...

Researchers uncovered how lung cells decide whether to rebuild tissue or fight infection. This built-in “switch” may be the ...

Receiving at least 2 COVID-19 vaccine doses is associated with lower rates of long COVID among adults in the United States, according to study results presented at IDWeek 2025, held from October 19 to ...